Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...
A panel determined that Tafinlar and Adcetris will be offered to certain patients but passed on several other precision therapies.
The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...
The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...
ATR 1072, a small interfering RNA drug, is Atrium's first precision cardiology program to enter the clinic since its launch earlier this year.
After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...
NEW YORK – The US Food and Drug Administration has cleared Umoja Biopharma to begin a Phase I/II trial for its CD22-directed in vivo CAR T-cell therapy, UB-VV400, in patients with relapsed or ...
Primary care docs in Sweden diagnosed Alzheimer's with the same accuracy as dementia specialists when they had access to beta ...
NEW YORK – AstraZeneca has acquired worldwide rights to develop and commercialize Dizal Pharmaceutical's EGFR inhibitor Zegfrovy (sunvozertinib) for up to $1.5 billion, the company announced Tuesday.
FDA Approves Celcuity's Revtorpyk Combo in HR-Positive, HER2-Negative, PIK3CA Wildtype Breast Cancer
NEW YORK – The US Food and Drug Administration on Tuesday approved Celcuity's PI3K/AKT/mTOR inhibitor Revtorpyk (gedatolisib) with fulvestrant and with or without Pfizer's Ibrance (palbociclib) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results